Human DAB2 interaction protein (DAB2IP) is a member of Ras-GTPase activating protein family and functions as a tumor suppressor, implying it could serve as a prognostic biomarker in cancers. Here we generated a mouse monoclonal antibody, 2A4, directed against human DAB2IP. This antibody was identified as IgG1 and specifically recognizes DAB2IP in both its native and denatured forms. It will serve as a useful and versatile tool for further mechanistic study and development of the potential prognostic significance of DAB2IP.
Get full access to this article
View all access options for this article.
References
1.
ChenH, PongRC, WangZ, and HsiehJT: Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics, 2002; 79:573–581.
2.
WangZ, TsengCP, PongRC, ChenH, McConnellJD, NavoneN, and HsiehJT: The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer—characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem, 2002; 277:12622–12631.
3.
FulopV, ColittiCV, GenestD, BerkowitzRS, YiuGK, NgSW, SzepesiJ, and MokSC: DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene, 1998; 17:419–424.
4.
TsengCP, ElyBD, PongRC, WangZ, ZhouJ, and HsiehJT: The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity—an underlying mechanism of its tumor-suppressive function in prostate cancer. J Biol Chem, 1999; 274:31981–31986.
5.
ZhouJ, and HsiehJT: The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade—DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem, 2001; 276:27793–27798.
6.
ZhouJ, ScholesJ, and HsiehJT: Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem, 2003; 278:6936–6941.
7.
MinJ, ZaslavskyA, FedeleG, McLaughlinSK, ReczekEE, De RaedtT, GuneyI, StrochlicDE, MacconaillLE, BeroukhimR, BronsonRT, RyeomS, HahnWC, LodaM, and CichowskiK: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med, 2010; 16:286–294.
8.
XieD, GoreC, ZhouJ, PongRC, ZhangH, YuL, VessellaRL, MinW, and HsiehJT: DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci USA, 2009; 106:19878–19883.
9.
ChambardJC, LeflochR, PouyssegurJ, and LenormandP: ERK implication in cell cycle regulation. Biochim Biophys Acta, 2007; 1773:1299–1310.
10.
ZhangR, HeX, LiuW, LuM, HsiehJT, and MinW: AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J Clin Invest, 2003; 111:1933–1943.
11.
ZhangH, ZhangR, LuoY, D'AlessioA, PoberJS, and MinW: AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. J Biol Chem, 2004; 279:44955–44965.
12.
XieD, GoreC, LiuJ, PongRC, MasonR, HaoG, LongM, KabbaniW, YuL, ZhangH, ChenH, SunX, BoothmanDA, MinW, and HsiehJT: Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci USA, 2010; 107:2485–2490.
13.
KongZ, RaghavanP, XieD, BoikeT, BurmaS, ChenD, ChakrabortyA, HsiehJT, and SahaD: Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells. Int J Radiat Oncol Biol Phys, 2010; 78:1210–1218.
14.
KongZ, XieD, BoikeT, RaghavanP, BurmaS, ChenDJ, HabibAA, ChakrabortyA, HsiehJT, and SahaD: Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res, 2010; 70:2829–2839.
15.
WuK, LiuJ, TsengSF, GoreC, NingZ, SharifiN, Fazli, GleaveM, KapurP, XiaoG, SunX, OzOK, MinW, AlexandrakisG, YangCR, HsiehCL, WuHC, HeD, XieD, and HsiehJT: The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene, 2014; 33:1954–1963.
16.
WuK, XieD, ZouY, ZhangT, PongRC, XiaoG, FazliL, GleaveM, HeD, BoothmanDA, and HsiehJT: The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res, 2013; 19:4740–4749.
17.
YunEJ, BaekST, XieD, TsengSF, DobinT, HernandezE, ZhouJ, ZhangL, YangJ, SunH, XiaoG, HeD, KittlerR, and HsiehJT: DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1. Oncogene, 2014; doi:10.1038/onc.2014.215.
18.
DoteH, ToyookaS, TsukudaK, YanoM, OuchidaM, DoiharaH, SuzukiM, ChenH, HsiehJT, GazdarAF, and ShimizuN: Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res, 2004; 10:2082–2089.
19.
DoteH, ToyookaS, TsukudaK, YanoM, OtaT, MurakamiM, NaitoM, ToyotaM, GazdarAF, and ShimizuN: Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer, 2005; 92:1117–1125.
20.
YanoM, ToyookaS, TsukudaK, DoteH, OuchidaM, HanabataT, AoeM, DateH, GazdarAF, and ShimizuN: Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer, 2005; 113:59–66.
21.
von BerghAR, WijersPM, GrootAJ, van Zelderen-BholaS, FalkenburgJH, KluinPM, and SchuuringE: Identification of a novel RAS GTPase-activating protein (RASGAP) gene at 9q34 as an MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosomes Cancer, 2004; 39:324–334.
22.
UhmKO, LeeES, LeeYM, ParkJS, KimSJ, KimBS, KimHS, and ParkSH: Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. J Korean Med Sci, 2009; 24:493–497.
23.
KyprianouN: ASK-ing EMT not to spread cancer. Proc Natl Acad Sci USA, 2010; 107:2731–2732.
24.
DengY, LeiM, ZhangW, LiW, ZhouE, LiuZ, and QiC: Monoclonal antibodies directed against Fpr3 protein as molecular chaperones. Hybridoma, 2011; 30:491–493.
25.
RzychonM, ZegersI, and SchimmelH: Analysis of the physicochemical state of C-reactive protein in different preparations including 2 certified reference materials. Clin Chem, 2010; 56:1475–1482.
26.
DuffyMJ, LamerzR, HaglundC, NicoliniA, KalousováM, HolubecL, and SturgeonC: Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer, 2014; 134:2513–2522.
27.
DuffyMJ, SturgeonC, LamerzR, HaglundC, HolubecVL, KlapdorR, NicoliniA, TopolcanO, and HeinemannV: Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol, 2010; 21:441–447.
